Chomogranin A, NSE, and 5-Hydroxyindolacetic Acid Measurements in Malignant Carcinoids Abstract #640

Introduction: GEP-NETs are a heterogeneous group of cancers more common in the small intestine which are usually asymptomatic. In patients with malignant carcinoids, a number of tumor markers (TMs) have been considered enclosing urinary 5-hydroxyindolacetic acid (5-HIAA), chromogranin A (CgA), and neuron-specific enolase (NSE) serum levels measurements. Unfortunately, the sensitivity of each TM largely depends on disease extent and the presence of functioning tumors, and thus their usefulness is still unclear.
Aim(s): To find a relationship between CgA, NSE, 5-HIAA and survival in patients with gastrointestinal carcinoids.
Materials and methods: Data regarding 14 patients (8 men, 6 women, median age 56 years, range 33-72) with histologically confirmed gastric (N=8), ileal (N=1), colorectal (N=4) and appendiceal (N=1) malignant carcinoids were reviewed. All patients underwent surgery, and four had liver metastases at the time of diagnosis.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Professor Franco Lumachi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids
Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Reidar Fossmark
#654 Identification of Signaling Pathways Involved in Lung Carcinoid Progression Using Gene Expression Profiling
Introduction: Lung carcinoids are well-differentiated neuroendocrine tumors (NETs) usually associated with a favorable prognosis. Mechanisms underlying progression are poorly understood.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MSc Dorian Swarts
#434 Treatment, Survival and Prognostic Markers in Patients with Thymic Carcinoids: A Clinicopathologic Study of 28 Cases
Introduction: Thymic carcinoids are uncommon but malignant tumors, usually associated with a poor prognosis. The number of cases reported is limited to a few hundred and there are few prognostic factors available.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Joakim Crona
#318 The SEER as a Prophet: Epidemiological Analysis as a Harbinger of Evolving Priorities in Gastroenteropancreatic Neuroendocrine Neoplasia
Introduction: Previous epidemiology analysis of tumor registries established that gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs) were both more prevalent, and more malignant, than previously recognized.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Mark Kidd
#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.